Relationship between vitamin D status in the first trimester of pregnancy and gestational diabetes mellitus - A nested case–control study

2021 ◽  
Vol 40 (1) ◽  
pp. 79-86
Author(s):  
Eleonora Salakos ◽  
Tioka Rabeony ◽  
Marie Courbebaisse ◽  
Joëlle Taieb ◽  
Vassilis Tsatsaris ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Vitamin D ◽  
Gestational Diabetes ◽  
Case Control Study ◽  
First Trimester ◽  
Case Control ◽  
Vitamin D Status ◽  
First Trimester Of Pregnancy ◽  
Nested Case Control ◽  
Control Study

scholarly journals Putrescine as a Novel Biomarker of Maternal Serum in First Trimester for the Prediction of Gestational Diabetes Mellitus: A Nested Case-Control Study

2021 ◽  
Vol 12 ◽  
Author(s):  
Cheng Liu ◽  
Yuanyuan Wang ◽  
Wei Zheng ◽  
Jia Wang ◽  
Ya Zhang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Case Control Study ◽  
Prediction Models ◽  
Fasting Blood Glucose ◽  
First Trimester ◽  
Case Control ◽  
Nested Case Control ◽  
Control Study

AimsEarly identification of gestational diabetes mellitus (GDM) aims to reduce the risk of adverse maternal and perinatal outcomes. Currently, no acknowledged biomarker has proven clinically useful for the accurate prediction of GDM. In this study, we tested whether serum putrescine level changed in the first trimester and could improve the prediction of GDM.MethodsThis study is a nested case-control study conducted in Beijing Obstetrics and Gynecology Hospital. We examined serum putrescine at 8-12 weeks pregnancy in 47 women with GDM and 47 age- and body mass index (BMI)-matched normoglycaemic women. Anthropometric, clinical and laboratory variables were obtained during the same period. The receiver operating characteristic (ROC) curve and area under the curve (AUC) were used to assess the discrimination and calibration of the prediction models.ResultsSerum putrescine in the first trimester was significantly higher in women who later developed GDM. When using putrescine alone to predict the risk of GDM, the AUC of the nomogram was 0.904 (sensitivity of 100% and specificity of 83%, 95% CI=0.832–0.976, P<0.001). When combined with traditional risk factors (prepregnant BMI and fasting blood glucose), the AUC was 0.951 (sensitivity of 89.4% and specificity of 91.5%, 95% CI=0.906-0.995, P<0.001).ConclusionThis study revealed that GDM women had an elevated level of serum putrescine in the first trimester. Circulating putrescine may serve as a valuable predictive biomarker for GDM.

scholarly journals A Prospective Nested Case-Control Study of Vitamin D Status and Pancreatic Cancer Risk in Male Smokers

2006 ◽  
Vol 66 (20) ◽  
pp. 10213-10219 ◽  
Author(s):  
Rachael Z. Stolzenberg-Solomon ◽  
Reinhold Vieth ◽  
Azar Azad ◽  
Pirjo Pietinen ◽  
Philip R. Taylor ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Vitamin D ◽  
Cancer Risk ◽  
Case Control Study ◽  
Case Control ◽  
Vitamin D Status ◽  
Pancreatic Cancer Risk ◽  
Nested Case Control ◽  
Control Study

First trimester prediction of gestational diabetes mellitus using plasma biomarkers: a case-control study

2019 ◽  
Vol 47 (2) ◽  
pp. 161-168 ◽  
Author(s):  
Paula J. Correa ◽  
Pia Venegas ◽  
Yasna Palmeiro ◽  
Daniela Albers ◽  
Gregory Rice ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Case Control Study ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
First Trimester ◽  
Case Control ◽  
Low Density ◽  
Control Study

AbstractObjectivesTo evaluate the first trimester maternal biomarkers for early pregnancy prediction of gestational diabetes mellitus (GDM).MethodsThe study was a case-control study of healthy women with singleton pregnancies at the first trimester carried out at the Obstetrics and Gynecology Unit, Clinica Davila, Santiago, Chile. After obtaining informed consent, peripheral blood samples of pregnant women under 14 weeks of gestation were collected. At 24–28 weeks of pregnancy, women were classified as GDM (n=16) or controls (n=80) based on the results of a 75-g oral glucose tolerance test (OGTT). In all women, we measured concentrations of fasting blood glucose, insulin, glycated hemoglobin, uric acid, cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), triglycerides, aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl transpeptidase (GGT), alkaline phosphatase (AP), sex hormone-binding globulin (SHBG), adiponectin, tissue plasminogen activator (t-PA), leptin and placental growth factor (PGF).ResultsThe GDM group displayed an increased median concentration of cholesterol (P=0.04), triglycerides (P=0.003), insulin (P=0.003), t-PA (P=0.0088) and homeostatic model assessment (HOMA) (P=0.003) and an increased mean concentration of LDL (P=0.009) when compared to the control group. The receiver operating characteristic (ROC) curve for significant variables achieved an area under the curve (AUC) of 0.870, a sensitivity of 81.4% and a specificity of 80.0%. The OGTT was positive for GDM according to the IADPSG (International Diabetes in Pregnancy Study Group) criteria.ConclusionWomen who subsequently developed GDM showed higher levels of blood-borne biomarkers during the first trimester, compared to women who did not develop GDM. These data warrant validation in a larger cohort.

scholarly journals Antidepressant use during pregnancy and the risk of gestational diabetes mellitus: a nested case–control study

BMJ Open ◽  
2019 ◽  
Vol 9 (9) ◽  
pp. e025908 ◽  
Author(s):  
Maëlle Dandjinou ◽  
Odile Sheehy ◽  
Anick Bérard
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Index Date ◽  
Case Control Study ◽  
Case Control ◽  
Increased Risk ◽  
Antidepressant Use ◽  
Nested Case Control ◽  
Control Study

ObjectivesThe aim of this study was to determine the association between antidepressant (AD) classes, types and duration of use during pregnancy and the risk of gestational diabetes mellitus (GDM).Design and settingA nested case–control study was conducted within the Quebec Pregnancy Cohort (QPC), a Canadian provincial database which includes data on all pregnancies and children in Quebec from January 1998 to December 2015.Primary outcome measuresGestational diabetes mellitus.ParticipantsCases of GDM were identified after week 20 of pregnancy and randomly matched 1:10 to controls on gestational age at index date (ie, calendar date of GDM) and year of pregnancy. AD exposure was assessed by filled prescriptions between the beginning of pregnancy (first day of last menstrual period) and index date. Conditional logistic regression models were used to estimate crude and adjusted odds ratios (aOR).ResultsAmong 20 905 cases and 209 050 matched controls, 9741 (4.2%) women were exposed to ADs. When adjusting for potential confounders, AD use was associated with an increased risk of GDM (aOR 1.19, 95% CI 1.08 to 1.30); venlafaxine (aOR 1.27, 95% CI 1.09 to 1.49) and amitriptyline (aOR 1.52, 95% CI 1.25 to 1.84) were also associated with an increased risk of GDM. Moreover, the risk of GDM was increased with longer duration of AD use, specifically for serotonin norepinephrine reuptake inhibitors, tricyclic ADs and combined use of two AD classes. No statistically significant association was observed for selective serotonin reuptake inhibitors.ConclusionThe findings suggest that ADs—and specifically venlafaxine and amitriptyline—were associated with an increased risk of GDM.

scholarly journals Serum placental growth factor in late first trimester of pregnancy for prediction of preeclampsia in primigravida - a case control study

2016 ◽  
Vol 6 (1) ◽  
pp. 106
Author(s):  
Rachna Agarwal ◽  
Shweta Chaudhary ◽  
Rajarshi Kar ◽  
Gita Radhakrishnan ◽  
Richa Sharma
Keyword(s):  
Case Control Study ◽  
Gestational Hypertension ◽  
Final Analysis ◽  
First Trimester ◽  
Case Control ◽  
Placental Growth Factor ◽  
Serum Samples ◽  
First Trimester Of Pregnancy ◽  
Nested Case Control ◽  
Control Study

Background: We studied the correlation of serum PLGF levels at 11-14 weeks in primigravida for prediction of future preeclampsia in a prospective nested case control study and estimated the critical levels of PLGF for possible use as screening test.Methods: Subjects with preeclampsia/gestational hypertension were taken as cases with an equal number of controls.Results: Out of 300 participants, final analysis was possible in 291 subjects. Thirty five were cases; two had early PE, 15 late PE and 18 had GH. PLGF level was lower in cases (20 pg/ml) compared to controls (79 pg/ml). PLGF was significantly lower in PE cases (15 pg/ml) compared to GH cases (34 pg/ml). PLGF had maximum area under the ROC curve (AUC) for PE with value of 0.867. Further, late PE had more AUC (0.853) as compared to GH (0.759). The cut off value for prediction of PE was found to be <30 pg/ml with 88.2% sensitivity and 71.4% specificity.Conclusions: PLGF levels were significantly lower in first trimester serum samples of subjects who later developed either preeclampsia or gestational hypertension. PLGF had better detection rate for PE and late PE as compared to GH.

Sign in / Sign up

Export Citation Format

Share Document